Clinical Trial

A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to see if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma who have not received treatment in the past. The study will also compare the combination of rituximab and ibrutinib with the combination of rituximab and placebo to see which combination works better.
Protocol Amendment History 22 amendments
This ClinicalTrials.gov record has been amended 22 times since 2019-12-23; most recent amendment 2026-07-22.
Status change: Recruiting → Active, Not Recruiting 2023-08-02
Trial Details
NCT Number NCT04212013
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Pharmacyclics LLC.
Conditions Marginal Zone Lymphoma
Enrollment 23 participants
Start Date 2019-12-23
Primary Completion 2027-03-18 (estimated)
Study Completion 2027-03-18 (estimated)
Updated on ClinicalTrials.gov 2026-07-23